Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy

T. Ando, K. Nakashima, H. Yoshita, M. Sakamura, M. Nomura, M. Muto, H. Fujii, Y. Horie, H. Takeda, T. Yoshi, T. Tahara, C. Katakda, K. Yoshimura, H. Ishikawa, A. Hosokawa

Department of Gastroenterology and Hematology, Faculty of Medicine, University of Tokyo, Tokyo, Japan; 2University of Miyazaki Hospital, Miyazaki, Japan; 3Department of Medical Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan; 4Department of Clinical Oncology, Jichi Medical University, Shimotsuke, Japan; 5Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan; 6Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan; 7Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan; 8Center for Integrated Medical Research, Hiroshima University Hospital, Hiroshima University, Hiroshima, Japan; 9Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan

Background: Both docetaxel and paclitaxel are a class of microtubule-stabilizing anticancer agents. Partial cross-resistance between docetaxel and paclitaxel was shown in breast and ovarian cancers. In advanced gastric cancer, retrospective study showed comparable efficacy of subsequent weekly paclitaxel with or without prior docetaxel-based chemotherapy. Therefore, we evaluated the efficacy and safety of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapy.

Methods: This study was a multi-center, single-arm phase II study in patients with advanced or recurrent esophageal cancer. Eligible criteria included histologically confirmed esophageal squamous cell carcinoma or adenosquamous carcinoma with measurable lesions, refractory to prior docetaxel-containing chemotherapy, aged 20 years and older, and an ECOG performance status (PS) of 0-1. Paclitaxel at 100 mg/m² was administered by intravenous infusion, and this was repeated weekly for 6 weeks followed by a 1-week rest. The primary end point was confirmed objective response rate (ORR), as assessed according to the RECIST version 1.1 criteria. The secondary end points included progression-free survival (PFS), overall survival (OS) and safety.

Results: Between January 2016 and November 2019, 25 patients were enrolled from 6 institutions in Japan. Two patients with ineligible (n=1) and refusal of treatment (n=1) were excluded. Therefore, 23 patients were included in this analysis. In prior treatment, all patients received fluoropyrimidine, platinum and docetaxel. The median number of treatment cycles was 2 (range 1–4). The ORR was 9% (2/23); however, the confirmed ORR was 6%. The disease control rate (DCR) was 52% (12/23). The median PFS and median OS were 81 days (95% confidence intervals (CI), 47 to 91), and 211 days (95% CI, 162 to 262), respectively. The common grade 3 or 4 treatment-related adverse events were neutropenia (34%), leukocytopenia (26%) and anaemia (22%). There were no treatment-related deaths.

Conclusions: Although this phase II study did not meet the primary endpoint, it showed modest efficacy with an acceptable safety profile.

Clinical trial identification: UMIN000019230. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosures: A. Hosokawa: Honoraria (self): Yakult Honsha, Taiho Pharmaceutical, Daiichi Sankyo, Chugai, Eisai, Lilly; Research (institution): Chugai Pharma, Taiho Pharmaceutical, Ono Pharmaceutical. All other authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2022.04.198

Safety and efficacy of GEMOX plus donafenib and tislelizumab as first-line therapy for advanced epithelial malignant biliary tract cancer

L. Wang, L. Wang, T. Zhang, Y. Zhao, A. Mao, W. Zhu, N. Zhang

Fudan University Shanghai Cancer Center, Shanghai, China

Background: Nearly 70% of the newly diagnosed patients with malignant biliary tract cancer (BTC) are in advanced stage. Gemcitabine-based systemic chemotherapy is the standard first-line treatment. Chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors as the first-line treatment has shown good efficacy but the safety profile remains to be improved. The purpose of this study was to evaluate the safety and efficacy of gemcitabine and oxaliplatin (GEMOX) plus donafenib and tislelizumab.

Methods: In this prospective single-center exploratory study, eligible patients were aged 18–80 years (inclusive) with histologically or cytologically documented stage III/IV (AJCC Cancer Staging Manual, 8th Edition) epithelial malignant biliary tract cancer, at least one measurable disease. The RECIST v1.1, ECOG performance status (PS) of 0–1, main organs function well and life expectancy of at least three months. Patients received gemcitabine 1000 mg/m² IV Q3W, oxaliplatin 100 mg/m² IV Q3W, donafenib 200 mg PO BID and tislelizumab 200 mg IV Q3W until disease progression, unacceptable toxicity or withdrawal of consent whichever occurred first. The primary endpoint was safety. The secondary endpoints included conversion rate and overall survival (OS).

Results: From March 2021 to August 2021, 13 patients were enrolled (5 males and 8 females; 4 stage III and 9 stage IV; all ECOG PS of 1; aged 53–72 years; 4 gallbladder cancer, 2 hilar cholangiocarcinoma and 7 intrahepatic cholangiocarcinoma). The median (IQR) levels of CA-199, AFP and CEA at baseline were 125 U/ml (4.5–1000), 3.5 mg/ml (1.8–11.4) and 6.3 ng/ml (1.6–12.8), respectively. At data cut-off (February 17, 2022), a median number of 4 cycles (range 1–14) of study treatment was received and the median treatment duration of donafenib was 87 days (range 17–277). The median follow-up time was 147 days (range 18–277). Treatment-related adverse events (TRAEs) occurred among all patients (100%), including 7 (53.8%) patients who had grade 3 TRAEs and one (7.7%) patient who had a grade 4 TRAE. No grade 5 TRAE or unexpected adverse event was reported. The most frequently reported grade 3-4 TRAEs were rash (4/13, 30.8%), platelet count decreased (2/13, 15.4%) and fatigue (2/13, 15.4%). Three stage III patients underwent subsequent surgery with a conversion rate of 23.1% (95% CI, 5.0%–53.8%). The median OS was not reached. The 6-month OS rate was 90.9% (95% CI, 50.8%–98.7%).

Conclusions: GemOX plus donafenib and tislelizumab as the first-line therapy for advanced BTC showed manageable toxicity and encouraging efficacy especially in terms of a promising conversion rate in stage III patients.

Clinical trial identification: NCT04979663. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosures: All authors have declared no conflicts of interest.

https://doi.org/10.1016/j.annonc.2022.04.200